Taiwanese clinical-stage biotech developing injectable drugs for localized fat reduction and other aesthetic/dermatology indications.
Taiwanese clinical-stage biotech developing injectable drugs for localized fat reduction and other aesthetic/dermatology indications.
Has no approved product, so it earns no product sales; it relies on money raised from investors and, if achieved, licensing deals with larger aesthetic-drug companies. Everything depends on trial results and regulatory approval of its injectable fat-reduction drug.
In one line: A Taiwanese peer to Allergan's Kybella developer.
Moat: narrow (IP / patents). Patent-protected injectable drug candidates in a clinical-stage pipeline, unproven commercially.
Headquarters: New Taipei City, Taiwan · Founded: 2012
Size Caliway Biopharmaceuticals (6919.TW) is a Taiwan Health Care company (Biotechnology) with a market value of $3.32B, the 110th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$72.00 on 18 Nov 2026.
Performance Over six months the shares fell 25.1%, against +5.5% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue fell 54.3% over the last twelve months (peer median +5.3%); the operating margin is -6,982.6% (peer median -2.3%).
Valuation It trades at 6,626.2× enterprise value to sales against a peer median of 8.5× (most expensive of 17).
Capital Return on invested capital runs 24.1 points below its cost of capital (6.9% WACC).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$16.0M | NT$38.0M | NT$44.4M | NT$38.9M | NT$12.8M |
| Revenue growth | — | -14% | +14% | +204% | — |
| Gross profit | -NT$17.5M | -NT$4.13M | NT$1.26M | -NT$398,000 | -NT$15.7M |
| EBITDA | -NT$1.09B | -NT$677M | -NT$688M | -NT$486M | -NT$294M |
| Net income | -NT$611M | -NT$352M | -NT$589M | -NT$488M | -NT$286M |
| Free cash flow | -NT$415M | -NT$442M | -NT$532M | -NT$433M | -NT$257M |
| Capital expenditure | NT$18.2M | NT$17.1M | NT$11.1M | NT$9.69M | NT$14.2M |
| Total debt | NT$231M | NT$3.00M | NT$31.6M | NT$20.5M | NT$28.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Caliway Biopharmaceuticals 6919.TW | $3.32B | -25% | -54% | -6,983% | 6,626.2× | n/a |
| AbbVie ABBV | $506B | +35% | +11% | 36% | 8.7× | -0.1% |
| Evolus EOLS | $468M | +7% | +14% | -5% | 1.8× | n/a |
| InMode INMD | $741M | -8% | +2% | 18% | 0.6× | -10.8% |
| Galderma GALD.SW | $51.9B | +18% | +16% | 19% | 9.7× | 18.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6919.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.4% | -4.6% | 9th lowest of 21 |
| 6-month return | -25.1% | +5.5% | 2nd lowest of 21 |
| Distance from 52-week high | -61.7% | -29.3% | 2nd lowest of 21 |
| Revenue growth (TTM) | -54.3% | +5.3% | 2nd lowest of 17 |
| Operating margin | -6,982.6% | -2.3% | lowest of 17 |
| EV / Sales | 6,626.2× | 8.5× | most expensive of 17 |
| ROIC minus cost of capital | -24.1 pp | -6.2 pp | 6th lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.32B | -25% | -54% | -6,983% | 6,626.2× | n/a | n/a |
| Enliven Therapeutics ELVN | United States | $3.30B | +7% | n/a | n/a | n/a | n/a | n/a |
| Hualan Biological Engineering 002007.SZ | China | $3.20B | -17% | -11% | 17% | 5.3× | 15.8% | -1.8% |
| Virbac VIRP.PA | France | $3.20B | -4% | +4% | 15% | 2.1× | 5.8% | +9.4% |
| Iovance Biotherapeutics IOVA | United States | $3.46B | +111% | +51% | -61% | 8.3× | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.47B | -13% | -13% | 21% | 4.5× | 2.2% | +12.5% |
| Disc Medicine IRON | United States | $3.55B | +16% | n/a | n/a | n/a | n/a | n/a |
| Xeris Biopharma XERS | United States | $3.10B | +173% | +38% | 13% | 8.7× | 29.5% | +70.2% |
| AbCellera Biologics ABCL | United States | $3.60B | +141% | +92% | -298% | 43.4× | n/a | n/a |
| Relay Therapeutics RLAY | United States | $3.65B | +27% | +24% | -3,095% | 273.1× | n/a | n/a |
| Joinn Laboratories (China) 603127.SS | China | $3.67B | -6% | +12% | -4% | 11.8× | n/a | n/a |
| ADMA Biologics ADMA | United States | $3.01B | +58% | +6% | 45% | 6.0× | -0.8% | +64.6% |
| Telix Pharmaceuticals TLX.AX | Australia | $2.99B | -2% | +27% | -1% | 3.8× | n/a | n/a |
| Tango Therapeutics TNGX | United States | $3.71B | +4% | -100% | n/a | n/a | n/a | n/a |
| Dyne Therapeutics DYN | United States | $2.97B | -10% | n/a | n/a | n/a | n/a | n/a |
| Denali Therapeutics DNLI | United States | $2.95B | -2% | n/a | -2,488% | 115.4× | n/a | n/a |
| Rubicon Research RUBICON.NS | India | $2.94B | +68% | +37% | 21% | 13.2× | n/a | n/a |
| XtalPi 2228.HK | Hong Kong | $2.87B | -34% | +4% | -127% | 21.3× | n/a | n/a |
| CRISPR Therapeutics CRSP | United States | $3.90B | -17% | -34% | -2,059% | 95.6× | n/a | n/a |
| Bavarian Nordic A/S BAVA.CO | Denmark | $2.82B | +23% | -8% | 18% | 2.6× | -4.3% | +27.4% |
| Zai Lab 9688.HK | Hong Kong | $2.79B | +23% | 0% | -63% | 5.4× | n/a | n/a |